Regentis Biomaterials Ltd. (RGNT)

NYSEAMERICAN: RGNT · USD

$1.37

+0.00 (0.0%)· Recorded snapshot

Market cap	9.6M
Net income (ttm)	-16.1M
EPS (ttm)	-$4.66
Shares out	7M
Volume	8,584.699

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -16.1M
EPS (ttm): -$4.66
Market cap: 9.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantenere

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 14:30 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROEn/a

P25 -113.8P50 -46.5P75 -0.9

ROIC-168.1

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All RGNT indicators

Market & fundamental data

Available fields

161

Groups with data

Currency

USD

Showing 161 of 161 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001912966
Company name	Regentis Biomaterials Ltd.
Country	Israel
Country code	US
CUSIP number	001219096
Earnings date	2026-09-11
Earnings time	bmo
Employees	7
Enterprise value	$699,772
Exchange	NYSEAMERICAN
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2004
Industry	Medical Instruments & Supplies
IPO date	2025-12-04
Is primary listing	Yes
Is SPAC	No
ISIN number	IL0012190968
Last 10-K release date	2026-02-24
Last earnings date	2026-09-11
Last refreshed	2026-11-04
Last stock split type	Never
Market cap	$9.6M
Market cap category	Nano-Cap
Next earnings date	2027-02-23
Options	No
Price	$1.37
Price currency	USD
Sector	Healthcare
SIC code	3842
Stock price date	2026-11-03
Symbol	RGNT
Tags	pharmaceuticals
Website	https://www.regentis.co.il

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-339.85%
FCF / EV yield	-553.75%
FCF yield	-40.27%
Industry forward P/E	22.48x
Industry P/E	61.2x
P/B ratio	1.25x
Price / tangible book value	1.25x
Sector forward P/E	24x
Sector P/E	49.18x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-2.3M
ROA	-113.59%
ROA (5Y)	-28.07%
ROCE	-115.96%
ROIC	-168.07%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-33,000
Depreciation and amortization	$5,000
EBIT	$-8.9M
EPS	$-4.66
FCF per share	$-0.55
Financing cash flow	$12.6M
Free cash flow	$-3.9M
Free cash flow minus SBC	$-11.4M
Investing cash flow	$-37,000
Net borrowing	$-1.2M
Net cash flow	$8.8M
Net income	$-16.1M
Operating cash flow minus SBC	$-11.3M
Operating income	$-8.9M
Stock-based compensation	$7.5M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$1.09
Debt / equity	0
Interest coverage	-113.01
Long-term assets	$64,000
Long-term liabilities	$18,000
Net cash (debt)	$8.9M
Net cash / market cap	92.73%
Net debt / equity	-1.16
Piotroski F-Score	2
Property, plant and equipment	$64,000
Shareholders' equity	$7.7M
Tangible book value	$7.7M
Tangible book value per share	$1.09
Total assets	$9.4M
Total cash	$9M
Total debt	$29,000
Total liabilities	$1.7M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$9.3M
Current liabilities	$1.7M
Current ratio	5.62
Net working capital	$-1.3M
Quick ratio	5.42
Working capital	$7.6M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-2,034.86%
Dividend yield	0%
Shareholder yield	-2,034.86%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$2.37
1D price change	0%
1M price change	-25.95%
1M total return	-25.95%
1W price change	6.2%
1W total return	6.2%
20-day SMA	$1.46
200-day SMA	$2.93
3M price change	-21.26%
3M total return	-21.26%
50-day SMA	$1.75
50-day SMA vs 200-day SMA	50under200
52-week high	$15.50
52-week high date	2026-06-15
52-week low	$1.23
52-week low date	2026-10-28
6M price change	-52.26%
6M total return	-52.26%
All-time high	$15.50
All-time high date	2026-06-15
All-time low	$1.23
All-time low date	2026-10-28
Average true range (ATR)	$0.12
Average volume	38.1K
Beta (1Y)	3.02
Change from 52-week high	-91.16%
Change from 52-week low	11.38%
Change from all-time high	-91.16%
Change from all-time low	11.38%
Change from open	0.74%
Day's gap	-0.73%
Dollar volume	$11,761
High price	$1.43
Low price	$1.34
Monthly RSI	0
Open price	$1.36
Position in 52-week range	33.33%
Premarket change	-2.19%
Premarket close	$1.37
Premarket price	$1.34
Premarket volume	2.7K
Previous close	$1.37
Price vs 150-day SMA	-42.22%
Price vs 20-day SMA	-5.84%
Price vs 200-day SMA	-53.27%
Price vs 50-day SMA	-21.58%
Relative volume	0.23
Return from IPO open	-81.49%
Return from IPO price	-82.88%
RSI	38.22
Sharpe ratio	0.5
Sortino ratio	3.08
Volume	8.6K
Weekly RSI	33.4
YTD price change	-79.67%
YTD total return	-79.67%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	4.3M
Float percentage	60.72%
Shares change (QoQ)	513.01%
Shares change (YoY)	2,034.86%
Shares held by insiders	1.83%
Shares held by institutions	7.63%
Shares outstanding	7M
Short % of float	0.29%
Short % of shares	0.18%
Short ratio	0.2 days

Deeper analysis on RGNT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this RGNT report

Is a complete RGNT research report available?

No complete published report is available for Regentis Biomaterials Ltd. (RGNT) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Regentis Biomaterials Ltd. (RGNT)

Price

Financial snapshot

Fair-value bridge

Latest news · RGNT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All RGNT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on RGNT

Frequently asked questions